In this presentation, Amy McMichael MD, discussed the latest updates in the treatment of common types of non-scarring alopecia, including pattern hair loss and alopecia areata (AA). She began by highlighting FDA-approved treatments for pattern hair loss, such as topical and oral minoxidil, finasteride, and low-level laser therapy, while also addressing emerging therapies like bicalutamide, sublingual minoxidil, and mesotherapy. The presentation emphasized the superior efficacy of oral dutasteride for male pattern hair loss compared to other therapies.

For AA, updates included the disproportionate prevalence in patients of color and the efficacy of JAK inhibitors like baricitinib, ritlecitinib, and deuruxolitinib, which are approved for severe AA in different age groups. A new tool, the Alopecia Areata Scale (AASc), was introduced to standardize the evaluation of AA severity and guide treatment decisions. The presentation also discussed combination treatments, side effects, and long-term safety data for JAK inhibitors.